Tamiflu (oseltamivir phosphate) for Oral Suspension: Label Change-New Concentration (6 mg/mL)

Audience: Pediatrics, Pharmacy Patients may potentially receive either concentration (6 mg/mL or 12 mg/mL) from their pharmacy during the next influenza season (2011-2012).
ISSUE: Labeling changes are being made to Tamiflu oral suspension to reduce…



Related posts:

  1. Chantix (varenicline): Label Change – Risk of Certain Cardiovascular Adverse Events Audience: Family Medicine, Cardiology [Posted 06/16/2011] ISSUE: FDA notified healthcare...
  2. Zocor (simvastatin): Label Change – New Restrictions, Contraindications, and Dose Limitations Audience: Family Practice, Cardiology, Pharmacy Simvastatin sold under the brand-name...
  3. Kaletra (lopinavir/ritonavir): Label Change – Serious Health Problems in Premature Babies Audience: Infectious Disease ISSUE: FDA notified healthcare professionals of serious...
  4. Topamax (topiramate): Label Change – Risk For Development of Cleft Lip and/or Cleft Palate in Newborns Audience: Neurology, OB/GYN ISSUE: FDA notified healthcare professionals and patients...